HC Wainwright Issues Negative Outlook for KROS Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Stock analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for Keros Therapeutics in a research note issued to investors on Friday, May 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($1.27) per share for the quarter, down from their prior estimate of ($0.91). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.93) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q3 2026 earnings at ($1.31) EPS, Q4 2026 earnings at ($1.33) EPS, FY2026 earnings at ($5.12) EPS, FY2027 earnings at ($5.88) EPS, FY2028 earnings at ($4.12) EPS, FY2029 earnings at ($2.41) EPS and FY2030 earnings at ($0.53) EPS.

Several other brokerages have also recently issued reports on KROS. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Finally, Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $20.40.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $10.16 on Tuesday. The business’s 50 day moving average price is $11.41 and its 200-day moving average price is $15.68. Keros Therapeutics has a fifty-two week low of $10.07 and a fifty-two week high of $22.55. The company has a market cap of $201.07 million, a price-to-earnings ratio of -3.38 and a beta of 0.95.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The company had revenue of $0.37 million for the quarter, compared to the consensus estimate of $1.93 million.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. AQR Capital Management LLC purchased a new position in Keros Therapeutics in the 1st quarter worth $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Keros Therapeutics by 15.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after acquiring an additional 2,982 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the last quarter. Creative Planning raised its stake in Keros Therapeutics by 40.2% in the 2nd quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Keros Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after acquiring an additional 7,146 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.